J&J’s Biosense Webster Touts Positive Data for QDOT MICRO Catheter

Biosense Webster, a Johnson & Johnson MedTech company, has released new findings from its Q-FFICIENCY study published in the Journal of Cardiovascular Electrophysiology showing that QDOT MICRO catheter treatment significantly improved control of atrial fibrillation (AFib), relief of symptoms, and overall quality of life.
 
The Q-FFICIENCY study evaluated safety and 12-month efficacy of the QDOT MICRO temperature-controlled, contact force-sensing, radiofrequency (RF) catheter in paroxysmal AFib patients. Based on patient-reported outcomes, 99% and 93.1% improvement in AFib control and AFib symptom relief were found, respectively.
 
The study also found 87.9% of patients had a meaningful clinical improvement in quality of life.
 
“These findings highlight the advantage of treatment with the QDOT MICRO Catheter in patients with paroxysmal AFib, demonstrating that patients have fewer symptoms and a significant improvement in their quality of life along with a low incidence of cardioversion and hospitalizations following temperature-controlled RF ablation treatment,” Ayman A. Hussein, MD, Director of Cardiac Electrophysiological Outcomes Research and Director of the Center for Atrial Fibrillation, Cleveland Clinic and the publication’s corresponding author, told the press. “Paired with previously published Q-FFICIENCY study data showing that the unique design of the QDOT MICRO Catheter enhanced efficiency and efficacy without compromising safety, the benefit of treatment with this state-of-the art tool is clear for both patients and physicians.”
 
According to Biosense Webster, QDOT MICRO incorporates advanced, high-energy ablation, improved temperature monitoring, optimized irrigation, and higher signal resolution. The device’s QMODE+ setting allows ablation delivery of 90 watts for up to four seconds. It’s integrated with the CARTO 3 system to enable efficient and consistent lesion creation, as well.
 
“AFib places a substantial burden on patients’ daily lives and healthcare resources, including physician visits, drug costs and side effects, and hospitalizations. At Biosense Webster, we are focused on improving patient outcomes, while offering innovative solutions for physicians treating the growing number of AFib patients today,” said Biosense Webster president Jasmina Brooks. “As the Q-FFICIENCY study findings demonstrate, use of the temperature-controlled QDOT MICRO Catheter allows physicians to customize treatment for each patient, reduce procedural times and offer significant benefits to patients through improving their quality of life.”